GlassScriptPhysician profile
Angela Lively
NPI 1043426737
$6,064.19
in general payments reported to CMS, 2019-2025
25 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $996 · 2023: $1,799 · 2024: $1,841 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,973 · Education: $95.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,972.54 |
| Education | $95.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,737.62 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $586.77 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $543.20 | 2022-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $419.47 | 2022-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $416.98 | 2022-2025 | |
| Ardelyx, INC. | $312.48 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $230.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $226.07 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $201.49 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $183.70 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $174.31 | 2023-2025 | Wegovy |
| Celltrion USA INC. | $157.67 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Gilead Sciences, INC. | $150.65 | 2022-2024 | |
| Lilly USA, LLC | $128.32 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $106.60 | 2024-2025 | Zenpep |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $94.46 | 2024-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $91.65 | 2024-2025 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $66.76 | 2023-2024 | Linzess |
| Celgene Corporation | $64.85 | 2023 | Zeposia |
| Coloplast Corp | $60.35 | 2024 | |
| Nestle Healthcare Nutrition INC. | $34.70 | 2022-2023 | |
| Braintree Laboratories, INC. | $32.09 | 2022-2024 | Suflave, Sutab |
| E.R. Squibb & Sons, L.L.C. | $16.10 | 2024 | Opdivo |
| Ferring Pharmaceuticals INC. | $13.65 | 2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $13.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Lively listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.